TerminatedPhase 1

Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia

Stopped: Unable to accrue subjects to the study.

United States1 participantsStarted 2012-04

Plain-language summary

The purpose of this study is to study the effect of eltrombopag on chemotherapy induced thrombocytopenia. Thrombocytopenia is when there is a low number of platelets in the blood. Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.

Who can participate

Age range18 Years – 82 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Metastatic soft tissue or bone sarcoma * 18 years of age or older * Adequate blood counts * Adequate kidney and liver function * At least 1 but no more than 3 prior systemic therapy regimens for this cancer * Good performance status - able to carry out work of a light or sedentary nature Exclusion Criteria: * Pre-existing hear disease such as congestive heart failure, or arrhythmia known to increase the risk of thromboembolic events (blood clots) * Blood clot in the last 6 months, known clotting problem or platelet disorder * History of brain cancer

What they're measuring

Tolerated Eltrombopag Dose

Timeframe: 1 year

Efficacy

Timeframe: 20 weeks

Trial details

NCT IDNCT01491594

SponsorDuke University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2013-03

View on ClinicalTrials.gov More Sarcoma, Soft Tissue trials